Placental pathology in fetuses with and without congenital heart defects Authors: Tucker E Doiron, Sherri Besmer, Jessenia Guerrero, Joanne Salas, Lauren Fox, Emily Zantow, Niraj R Chavan Published: 2026 ABSTRACT AbstractIntroductionPlacental histopathologic evaluation of pregnancies affected by congenital heart defects (CHDs) can provide insight into the mechanism connecting placental and fetal vascular systems. The objective of this study was to evaluate the prevalence of maternal vascular malperfusion (MVM) and fetal vascular malperfusion (FVM) lesions of the placenta in pregnancies with and without fetal CHD on blinded pathologic examination.MethodsThis is a case‐control study of pregnancies complicated by CHD at our institution from January 1, 2011 to June 25, 2021. Controls were matched to cases in a 2:1 ratio based on maternal age and gestational age at delivery. Placental and umbilical cord pathology slides were deidentified prior to standardized pathologic examination. There were two primary composite outcomes: MVM and FVM. The MVM composite included infarction and villous and vascular lesions. The FVM composite included thrombosis, villous lesions, and cord abnormalities. Primary composite outcomes were evaluated based on the presence or absence of a fetal CHD using t‐tests and chi‐squared or Fisher's exact tests, and a multivariable, conditional logistic regression model controlling for relevant confounding variables. Subgroup analysis was performed for those with and without maternal cardiovascular risk factors in the CHD group and for primary outcomes by cardiac lesion type.ResultsA total of 351 patients were included: 117 cases and 234 controls. The CHD cohort had higher rates of neonatal intensive care unit (NICU) admission (91.5% vs. 22.2%, p < 0.001), neonatal death (12.8% vs. 0%, p < 0.001), and placental chorangiosis (12.0% vs. 4.7%, p = 0.01). Pregnancies with CHD were also more likely to have the FVM composite outcome (odds ratio [OR], 1.88; confidence interval [CI], 1.20–2.97), specifically villous lesions (26.5% vs. 10.7%, p = 0.0001), avascular villi (22.2% vs. 9.8%, p = 0.002), and a two‐vessel umbilical cord (6.8% vs. 0.9%, p = 0.003). The MVM composite did not differ between groups. In the multivariable regression, the CHD group had higher odds of experiencing the FVM composite (OR, 2.01; CI, 1.14–3.56). Within the CHD cohort, those with hypertensive disorders of pregnancy were associated with the MVM composite outcome (53.9% vs. 36.2%, p = 0.05).ConclusionsOn blinded pathology review, those with fetal CHD were more likely to have FVM lesions. MVM lesions did not show an association with CHD in our cohort.Keywords: fetal congenital heart defect, pathology, placenta INTRODUCTION Congenital heart defects (CHDs) are defined as a structural defect in either the heart and/or the great vessels that are present at the time of birth [1]. CHDs affect about 5 to 15 per 1000 live births [2] and make up roughly 26% of birth defect–related infant deaths in the United States [3]. An association between the development of the placental and fetal circulations has been proposed based on concurrent organogenesis, biomechanical cues, and angiogenic imbalance [4, 5, 6, 7]. However, the exact relationship between placental and fetal vascular systems in the context of fetal anomalies and specifically in the context of fetal CHD remains poorly understood. The Amsterdam criteria were established in 2015 and include a categorization of placental lesions into maternal and fetal perfusion defects [8]. There is an association between spontaneous preterm birth, fetal growth restriction (FGR), hypertensive disorders of pregnancy (HDPs), and maternal vascular malperfusion (MVM) lesions [9]. Fetal vascular malperfusion (FVM) lesions are typically seen in association with umbilical cord (UC) obstruction [10] or other causes of inadequate perfusion of the distal villous tree, such as fetal hyperviscosity, thrombophilias, or CHD [4, 11]. The occurrence of fetal CHD has also been shown to be associated with maternal cardiovascular risk (CVR) factors such as diabetes (pregestational and gestational) and hypertension (pre‐existing chronic hypertension [CHTN] and pregnancy‐related hypertension) [12, 13, 14]. An imbalance in angiogenic factors has been linked to both CHD and the development of placental dysfunction (FGR, preeclampsia) [4]. Although associations have been shown between these maternal risk factors and an increased prevalence of fetal CHD [12, 13, 14], the pathophysiologic mechanism is not fully understood and warrants further investigation. We sought to compare placental pathology findings among pregnancies with and without CHD by undertaking a blinded review of placental and UC specimens. The objective of this study was to evaluate the incidence of MVM and FVM lesions among pregnancies with and without CHD as well as the impact of maternal CVR on this relationship. We hypothesized that placentas from pregnancies complicated by CHD were more likely to have abnormal findings on pathologic examination, especially fetal malperfusion lesions compared to controls. MATERIALS AND METHODS This is a case‐control study with controls matched to cases in a 2:1 ratio based on review of placental and UC pathology specimens. Case review and data abstraction were performed from charts of patients with pregnancies complicated by CHD who received care and delivered at our institution from January 1, 2011 to June 25, 2021. A query of our ultrasound database was performed to identify cases of CHD. Patients with multiple gestation, fetuses with other major anomalies or aneuploidy, and those without reviewable placental pathology slides were excluded. Patients with singleton pregnancies not complicated by fetal CHD or any other major anomalies served as controls from a cohort of deliveries where pathologic examination of the placenta was requested due to a clinical indication (such as chorioamnionitis, gross abnormalities, or maternal comorbidities) and available for review. Controls were matched based on gestational age (within 1 week) and maternal age at delivery. The study was approved by our Institutional Review Board. CHDs were diagnosed on antenatal ultrasound and must have been confirmed by a postnatal echocardiogram. CHDs included double outlet right ventricle (DORV), transposition of the great arteries (TGA), atrioventricular (AV) canal defect, tetralogy of Fallot (TOF), tricuspid atresia or stenosis, hypoplastic left heart syndrome (HLHS), atresia of the pulmonary artery, total anomalous pulmonary venous return (TAPVR), truncus arteriosus, pulmonary or aortic valve stenosis, coarctation of the aorta, pulmonary artery stenosis, and ventricular and atrial septal defects (VSD/ASD). Three pediatric pathologists were interpreting the slides. Interpretations for the study were performed separately from and after initial clinical evaluation—often performed years prior. Pathologists were blinded to the pregnancy outcome (except for gestational age at delivery and birthweight) as well as to the presence or absence of a CHD. Pathologists were given the blinded slides and a standardized worksheet (Appendix A in the Supporting Information) including a list of placental and UC lesions chosen from the Amsterdam criteria [9] known to be associated with maternal and fetal vascular pathology as well as miscellaneous lesions. Our study had two primary composite outcomes due to the different pathophysiologic pathways involved in each consideration: an MVM composite and an FVM composite. The MVM composite consisted of any of the following—infarction (central or marginal) ≥5%, villous changes (accelerated villous maturation, increased syncytial knots, villous agglutination, increased intervillous fibrin deposition, or distal villous hypoplasia), and vascular lesions (acute atherosis, mural hypertrophy, or basal decidual vascular thrombi). The FVM composite consisted of any of the following—fetal vascular thrombosis, villous lesions (villi with stromal vascular karyorrhexis, or avascular villi), and cord abnormalities (hypercoiled, hypocoiled, two‐vessel cord, or marginal cord insertion). All analyses were conducted using SAS v9.4 (SAS Institute) at a two‐tailed alpha = 0.05. Means and standard deviations, and frequencies and percentages were used to describe characteristics. Crude, bivariate associations of maternal characteristics, comorbidities, and birth characteristics were compared between cases and controls using independent samples t‐tests, chi‐square tests, or Fisher's exact tests, where appropriate. Crude and fully adjusted conditional logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the association of CHD status with composite outcomes (i.e., MVM and FVM). Fully adjusted models included race, payer source, FGR, maternal hypertension, diabetes, tobacco use, and body mass index (BMI). Maternal age and gestational age were not included as these were matching variables. An exploration of the relationship of the presence or absence of component outcomes with CHD status was crudely assessed with chi‐square or Fisher's exact tests. Among patients with CHD, MVM and FVM outcomes were compared between patients with and without: (a) cardiovascular risk factors (i.e., any diabetes or hypertension); (b) any diabetes; (c) any hypertension; (d) HDP; and (e) gestational diabetes, using Fisher's exact or chi‐square tests. The composite outcomes were then evaluated by cardiac lesion type categorizing as left‐sided, right‐sided, septal, or conotruncal lesions. Cases were classified into each category by the primary lesion type. The left‐sided lesions included hypoplastic left heart, aortic valve stenosis, and aortic arch coarctation/hypoplasia. The right‐sided lesions included tricuspid atresia or stenosis, pulmonary artery atresia, TAPVR, and pulmonary valve stenosis. Septal lesions included AV canal defects, ASDs, and VSDs. Conotruncal lesions included DORV, TGA, and truncus arteriosis. RESULTS A total of 351 patients were included in the study cohort: 117 CHD cases and 234 controls. Baseline maternal, fetal, and neonatal characteristics of the cohort are described in Table 1. Patients in the overall cohort were predominantly black (61.5% vs. 31.9%, p < 0.001) and had public insurance (71.5% vs. 26.8%, p = 0.002). The non‐CHD group had a higher overall mean BMI (32.9 ± 8.7 vs. 30.4 ± 7.8 kg/m2, p = 0.009) and was more likely to have gestational diabetes (18.4% vs. 9.4%, p = 0.029) and CHTN (21.8% vs. 11.1%, p = 0.015). There was no difference in the rate of HDP between the two groups (22.2% vs. 23.1%, p = 0.857). The CHD group had a higher rate of FGR (27.4% vs. 13.7%, p = 0.002), neonatal intensive care unit (NICU) admission (91.5% vs. 22.2%, p < 0.001), and neonatal death (12.8% vs. 0%, p < 0.001). TABLE 1Patient characteristics of patients pregnant with fetuses with and without a congenital heart defect (CHD) (n = 351). Characteristics n (%), mean (± SD) Overall cohort (n = 351) CHD (n = 117) No CHD (n = 234) p valueMaternal characteristicsRace/ethnicity<0.0001White, NH112 (31.9)71 (60.7)41 (17.5)Black, NH216 (61.5)40 (34.2)176 (75.2)Other, NH10 (2.9)3 (2.6)7 (3.0)Hispanic13 (3.7)3 (2.6)10 (4.3)Primary payer source0.002Public251 (71.5)70 (59.8)181 (77.4)Private94 (26.8)45 (38.5)49 (20.9)Self‐pay/none2 (0.6)1 (0.9)1 (0.4)Unknown4 (1.1)1 (0.9)3 (1.3)Gravity—primigravid80 (22.8)33 (28.2)47 (20.1)0.087BMI (kg/m2) at first prenatal encounter32.1 (± 8.5)30.4 (± 7.8)32.9 (± 8.7)0.009Pregnancy comorbiditiesDiabetes mellitus104 (29.6)23 (19.7)81 (34.6)0.004Pregestational50 (14.3)12 (10.3)38 (16.2)0.131Gestational54 (15.4)11 (9.4)43 (18.4)0.029Chronic hypertension64 (18.2)13 (11.1)51 (21.8)0.015Hypertensive disorder of pregnancy80 (22.8)26 (22.2)54 (23.1)0.857Gestational hypertension11 (3.1)3 (2.6)8 (3.4)0.758Preeclampsia/Eclampsia18 (5.1)9 (7.7)9 (3.9)0.124HELLP53 (15.1)16 (13.7)37 (15.8)0.598Current substance abuse97 (27.6)35 (29.9)62 (29.5)0.500Tobacco78 (22.2)28 (23.9)50 (21.4)0.586Alcohol11 (3.1)4 (3.4)7 (3.0)1.00Other42 (12.0)14 (12.0)28 (12.0)1.00Fetal growth restriction64 (18.2)32 (27.4)32 (13.7)0.002Delivery characteristicsGestational age at delivery (weeks)37.7 (± 2.5)37.5 (± 2.7)37.8 (± 2.4)0.344PTB70 (19.9)25 (21.4)45 (19.2)0.637Mode of delivery:0.111Vaginal delivery192 (54.7)71 (60.7)121 (51.7)Cesarean section159 (45.3)46 (39.3)113 (48.3)Birthweight (g)2920.7 (± 726.4)2836.0 (± 758.4)2963.0 (± 707.8)0.123NICU admission159 (45.3)107 (91.5)52 (22.2)<0.0001Neonatal death15 (4.3)15 (12.8)0 (0.0)<0.0001Abbreviations: HELLP, hemolysis elevated liver enzymes and low platelets; NH, non‐Hispanic; NICU, neonatal intensive care unit; PTB, preterm birth. Patient characteristics of patients pregnant with fetuses with and without a congenital heart defect (CHD) (n = 351). Characteristics n (%), mean (± SD) Overall cohort (n = 351) CHD (n = 117) Abbreviations: HELLP, hemolysis elevated liver enzymes and low platelets; NH, non‐Hispanic; NICU, neonatal intensive care unit; PTB, preterm birth. Pregnancies complicated by CHD were more likely to have the FVM composite outcome (OR, 1.88; CI, 1.20–2.97) when compared to those without CHD (Table 2). Specific lesions included villous lesions (26.5% vs. 10.7%, p < 0.001), avascular villi (22.2% vs. 9.8%, p = 0.002), and a two‐vessel UC (6.8% vs. 0.9%, p = 0.003). There was no significant difference in the MVM composite outcome between the CHD and non‐CHD groups (OR, 1.32; CI, 0.80–2.16). TABLE 2Primary outcomes with individual variables included in the Composite (n = 351). CHD (n = 117) No CHD (n = 234) p value or crude OR (95% CI) a MVM Composite44 (37.6)75 (32.1)1.32 (0.80–2.16)Central Infarction ≥5%4 (3.4)2 (0.9)0.098Marginal Infarction ≥5%1 (0.9)3 (1.3)1.00Villous changes31 (26.5)56 (23.9)0.600Accelerated villous maturation4 (3.4)14 (6.0)0.442Increased syncytial knots12 (10.3)15 (6.4)0.209Villous agglutination14 (12.0)21 (9.0)0.378Increased intervillous fibrin deposition12 (10.3)24 (10.3)1.00Distal villous hypoplasia0 (0.0)4 (1.7)0.306Vascular lesions15 (12.8)34 (14.5)0.663Acute atherosis4 (3.4)8 (3.4)1.00Mural hypertrophy9 (7.7)24 (10.3)0.438Basal decidual vascular thrombi2 (1.7)5 (2.1)1.00FVM Composite56 (47.9)76 (32.5)1.88 (1.20‐2.97)Fetal vascular thrombosis15 (12.8)22 (9.4)0.326Villous lesion31 (26.5)25 (10.7)0.0001Villi with stromal vascular karyorrhexis9 (7.7)9 (3.9)0.124Avascular villi26 (22.2)23 (9.8)0.002Cord abnormality26 (22.2)47 (20.1)0.642Hypercoiled0 (0.0)1 (0.4)1.00Hypocoiled1 (0.9)4 (1.7)0.668Two‐vessel cord8 (6.8)2 (0.9)0.003Marginal cord insertion13 (11.1)32 (13.7)0.498 a p value: chi‐square or Fisher's exact test for components; odds ratio (OR): crude OR from conditional logistic regression analysis for major composite outcome categories (MVM = maternal vascular malperfusion and FVM = fetal vascular malperfusion). Primary outcomes with individual variables included in the Composite (n = 351). CHD (n = 117) p value: chi‐square or Fisher's exact test for components; odds ratio (OR): crude OR from conditional logistic regression analysis for major composite outcome categories (MVM = maternal vascular malperfusion and FVM = fetal vascular malperfusion). When adjusting for race/ethnicity, primary payer, all hypertension, all diabetes, tobacco use, FGR, and BMI, those with CHD‐affected pregnancies had increased odds of experiencing the FVM composite outcome (adjusted OR 2.01; CI, 1.14–3.56) (Figure 1A). There was no significant relationship between CHD and the MVM composite outcome (OR, 1.32; CI, 0.72–2.42) (Figure 1B) in the adjusted regression analyses. FGR was independently associated with higher odds of having the MVM composite outcome (OR, 2.71; CI, 1.01–7.29). (A) Conditional logistic regression for FVM with adjusted odds ratios. (B) Conditional logistic regression for MVM with adjusted odds ratios. FVM, fetal vascular malperfusion; MVM, maternal vascular malperfusion. Among those in the CHD group, MVM and FVM composites were evaluated based on the presence of maternal CVR (Table 3a). No significant differences between the CVR and non‐CVR groups were noted when evaluating for MVM and FVM composites (32.9% vs. 46.3%, p = 0.152; 47.2% vs. 48.8%, p = 0.884). Subgroup analysis among cases with prepregnancy HTN and prepregnancy diabetes independently showed no statistical difference (Table 3b). Those with an HDP were more likely to have the MVM composite as compared to those without an HDP (53.9% vs. 33.0%, p = 0.05). There were no differences in the rates of the composite outcomes noted between cases of CHD with and without gestational diabetes (Table 3c). TABLE 3Placental perfusion defect lesions and presence of maternal cardiovascular risk factors (CVR) in those with fetal congenital heart defects (n = 117).(a) Overall maternal CVR No CVR (n = 76) CVR (n = 41) p value MVM composite25 (32.9)19 (46.3)0.152FVM composite36 (47.4)20 (48.8)0.884(b) Hypertension No hypertension (n = 86) Hypertension (n = 31) MVM composite28 (32.6)16 (51.6)0.060FVM composite40 (46.5)16 (51.6)0.626 No HDP (n = 91) HDP (n = 26) MVM composite30 (33.0)14 (53.9)0.053FVM composite43 (47.3)13 (50.0)0.805(c) Diabetes No diabetes (n = 94) Diabetes (n = 23) MVM composite34 (36.2)10 (43.5)0.517FVM composite43 (45.7)13 (56.5)0.354 No gestational diabetes (n = 106) Gestational diabetes (n = 11) MVM composite39 (36.8)5 (45.5)0.745FVM composite53 (50.0)3 (27.3)0.209Abbreviations: FVM, fetal vascular malperfusion; HDP, hypertensive disorders of pregnancy; MVM, maternal vascular malperfusion. Placental perfusion defect lesions and presence of maternal cardiovascular risk factors (CVR) in those with fetal congenital heart defects (n = 117). Abbreviations: FVM, fetal vascular malperfusion; HDP, hypertensive disorders of pregnancy; MVM, maternal vascular malperfusion. On evaluation of other placental lesions (Table S1), the non‐CHD group was more likely to have evidence of a maternal inflammatory response (MIR) (30.8% vs. 19.7%, p = 0.027) and fetal inflammatory response (FIR) (26.9% vs. 16.2%, p = 0.026). The CHD group had higher rates of chorangiosis (12.0% vs. 4.7%, p = 0.013) and placentas were more likely to be less than the 10th percentile for weight (29.9% vs. 0.4%, p = 0.001). MVM and FVM composites as well as independent placental lesions were evaluated by CHD category (Table S2). Due to small sample sizes, this evaluation is somewhat exploratory in nature. Septal lesions, when compared to left, right, and conotruncal lesions, had higher rates of several lesions (Table S2). Sensitivity analysis was performed by removing FGR from the adjusted models and evaluating the rates of the FVM and MVM composites. Removing FGR as a confounder did not significantly affect the results (Table S3). Additionally, removing cord abnormalities from the FVM composite definition did not impact the rate of the FVM composite outcome when comparing the CHD versus the non‐CHD groups. DISCUSSION Pregnancies complicated by CHDs were more likely to have the FVM composite on standardized, blinded placental pathology review. The rate of the MVM composite was not different between CHD and controls. Our cohorts had significant differences in race/ethnicity and payer. The presence of combined maternal CVR did not increase the rate of the MVM or FVM composite in the CHD group; however, the presence of HDP alone increased the rate of the MVM composite. Pregnancies complicated by fetal CHD were more likely to have placental weights <10th percentile and higher rates of chorangiosis. When evaluating specific types of CHDs, rates of certain placental lesions (accelerated villous maturation, increased syncytial knots, vascular lesions, mural hypertrophy, and thrombosis) differed significantly based on the type of CHD lesion with a preponderance for these to occur in pregnancies with septal lesions. A relationship between the development of the placental circulation and the fetal circulation has been proposed [4]. Along with concurrent organogenesis of the fetal and placental circulation, a mechanism of altered oxygen and nutrient transport through placental circulation may significantly impact organogenesis of the fetal cardiovascular system [5]. Resistance in the arterial and capillary networks within the placenta can vary with pathologic lesions of the placenta [7]. Cardiac gene expression has been shown to be sensitive to biomechanical cues; therefore, variances in resistance to flow may influence the differentiation of cardiomyocytes and morphogenesis of the fetal heart [6]. Similarly, experiments on chick embryos showed that altering blood flow to the inflow and outflow tracts of the developing heart caused cardiac malformations [7]. Changes in the development of the chorionic vessels can increase the risk for vasculopathies of the placenta, which carries a sixfold increase in the development of CHD [4]. Frequencies of MVM and FVM lesions in a retrospective study evaluating term pregnancies with normal outcomes were 35.6% and 19.7%, respectively [15]; however, other studies have shown frequencies as low as 1.3% and 2.7% [16], and 24.5% and 7.9% [17]. In our study, frequencies of the MVM and FVM composites in the non‐CHD group were 32.1% and 32.5%, respectively, and 37.6% and 47.9% in the CHD group, likely due to the higher rate of pregnancy comorbidities in our cohort compared with other studies. One previously published study with an overall sample size of 139 patients (47 cases and 92 controls) found that CHDs were associated with higher rates of placental perfusion defects (PPDs); specifically, both FVM and MVM [10]. This study included only severe CHDs that required surgery or catheterization within the first year of life [10]. In contrast, our study had broader inclusion criteria for CHDs in order to capture a wider array of pathologic lesions. This suggests the plausibility of a relationship between more severe CHDs and a higher rate of MVM lesions. This prior study also evaluated maternal CVR (diabetes, CHTN, gestational hypertension, or preeclampsia) [10]; they found that those with CHD and maternal risk factors had higher rates of both MVM and FVM lesions, unlike our results; although overall numbers in the cohorts were low [10]. Placental FVM lesions have been shown to be associated with obstructive UC lesions [11]. Obstructive UC lesions cause stasis resulting in ischemic damage to the terminal villi in the basal plate [11]. UC obstruction is thought to be the one of the leading causes of FVM and can be due to either acute clinical conditions, anatomic UC characteristics, or fetal conditions. More acute clinical conditions causing UC obstruction include entanglements, cord prolapse, or oligohydramnios [11]. Anatomic causes of UC obstruction include a long or hypercoiled cord, a marginal or furcate insertion, or a true knot [11]. Other causes of UC compression are fetal conditions that lead to stasis and inadequate perfusion of the distal villous tree such as fetal cardiac defects, which contribute to FVM lesions [11]. This is consistent with the results of our study. Of note, our cohort had only one patient with a hypercoiled cord. Although there is an increased frequency of marginal cord insertion noted in the literature for those with CHD [4, 18, 19], it is unclear exactly how it is associated with the fetal placental‐heart axis during embryogenesis; however, on sensitivity analysis removing cord abnormalities, the increased rate of the FVM composite in the CHD group persisted. In our cohort, we found no significant differences in the rates of marginal cord insertion between the CHD and non‐CHD groups. This discrepancy could possibly be explained by the interpreting pathologists only having access to the gross description at the time of evaluation for the placenta and UC specimens, which was not standardized and potentially led to underrepresentation of these cases in our cohort. This could also explain the increased rate of marginal cord insertion in the control group above expected given that these placental specimens were originally sent for a specific clinical indication. In MVM lesions, partial or complete occlusion from the spiral arteries leads to accelerated villous maturation or, in severe cases, villous infarct [11]. MVM lesions are proposed to develop from dysfunction in the normal vascular remodeling process of early pregnancy that creates the low‐resistance, high‐capacitance system of an effective placenta [10]. MVM lesions are most commonly seen with conditions such as HDP, FGR, and spontaneous preterm birth [20]. A recent study evaluated MVM lesions in pregnancies affected by fetal CHD [19] and found an increased rate of MVM lesions in those pregnancies when compared to controls. We showed a trend toward higher odds of the MVM composite in the CHD group in our study; however, it did not reach statistical significance. The previously mentioned study [19] was retrospective in nature, did not have a standardized pathology review, and patients in the control group were without pregnancy complications (diabetes, hypertensive disorders, or complications during labor and delivery). In contrast, our study employed standardized, prospective, blinded pathology review, which ensured the same lesions were being evaluated for each patient. Our control group had slightly higher rates of CHTN, diabetes, and a higher mean BMI, which could influence the prevalence of MVM lesions in this group. In our study, FGR was twice as common in the CHD group. Fetal growth restriction has been shown to be associated with CHD when compared to pregnancies without CHD; however, it is unclear if FGR is fundamentally linked to CHD or if there is just a greater chance of identification of FGR in anomalous pregnancies [21]. When controlling for FGR, the FVM composite remained more likely to occur in the CHD group. Because it is unclear whether FGR is a confounder or on the causal pathway to placental malperfusion lesions, sensitivity analysis with FGR excluded from the model maintained this relationship (Table S3). Independently, pregnancies affected by FGR in both groups had higher odds of MVM lesions, which is consistent with what is reported in the literature to date [9]. We found smaller placental size in the CHD group and higher rates of chorangiosis. Several studies have also previously noted that pregnancies affected by CHD are associated with smaller placental size compared to pregnancies without fetal CHD likely due to changes in oxygenation [18, 20, 22], which is consistent with the findings in our study. Our study also found a significant rate of chorangiosis in the CHD group compared with controls, which is a lesion associated with chronic hypoxia as well [23] and has been previously reported in those with CHD [18, 24]. Our non‐CHD group had higher rates of MIR and FIR, which is likely due to this group having an indication for placental pathology (i.e., chorioamnionitis). Strengths of our study most notably include blinding the interpreting pathologists to the fetal anomaly and clinical outcome, reducing bias in assessments of both cases and controls and, to our knowledge, is the only study evaluating MVM and FVM lesions of its kind. We provided a standardized worksheet for placental pathology evaluation based on the Amsterdam criteria, ensuring that all cases and controls were evaluated for the same lesions. We also had a much larger sample size compared to other studies of its kind. Our composite outcomes were well‐defined and based on the expert opinion of our pediatric pathologists and review of the literature making our results more clinically impactful. This study is not without its limitations. Given the extended time period used to collect the sample, there was variance in the language and components included in the original pathology reports. This may have led to variation in reporting and appreciation of gross pathology findings and makes it impossible to compare blinded to unblinded reviews. There is a possibility that the limited gross descriptions from the original pathology review could have biased the blinded pathologies but we anticipate this to be evenly distributed across the groups. There was also an unintended selection bias in our control group because patients who were more likely to have their placentas sent for pathologic evaluation are more likely to have pregnancy or delivery comorbidities, potentially increasing the baseline rate of placental lesions in controls. This likely also made interpretation of rates of MVM lesions in the control group higher than a normal obstetric population. There is also the possibility of ascertainment bias of the reviewing pathologists but due to blinding we anticipate this to be evenly distributed across groups. When evaluating by lesion types (left, right, septal, and conotruncal), the sample sizes become much smaller, making comparison between the groups harder to interpret and more exploratory in nature. Owing to the nature of the study—the temporal trend between the development of the placental lesions and the CHD cannot be established. CONCLUSION In conclusion, fetal CHDs are associated with higher rates of FVM lesions but not with MVM lesions compared to the non‐CHD group when controlling for pregnancy comorbidities. Those with FGR across both groups had higher odds of MVM lesions. The findings of our study provide further evidence to support the theory of the placental‐heart axis during embryogenesis. Our data add new insights to the mechanistic pathway between the fetal heart and the placenta, specifically in relation to the presence of FVM lesions. Further translational studies are needed to better understand the associations between the development of the placenta and the fetal heart and pregnancy comorbidities that can influence this relationship. CONFLICT OF INTEREST STATEMENT The authors declare no conflicts of interest. ETHICS STATEMENT This study received Saint Louis University Institutional Review Board Approval # #31998. Supporting information Supporting information Supporting information ACKNOWLEDGEMENTS This study has received the Saint Louis University Graduate Medical Education Advanced Health Data Research Training Grant for statistical support. REFERENCES Associated Data Supplementary Materials Supporting information Supporting information